NET PROFIT (x1000 EUR)
EMPLOYEES
Asarina Pharma AB (publ)
Closing information (x1000 EUR)
| Closing information | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
| Turnover |
0
|
0
|
0 |
| Financial expenses |
10
|
39
|
51 |
| Earnings before taxes |
-1,314
|
-1,332
|
-3,745 |
| EBITDA |
-1,281
|
-1,283
|
-3,706 |
| Total assets |
548
|
1,515
|
2,969 |
| Current assets |
477
|
1,409
|
2,824 |
| Current liabilities |
399
|
203
|
901 |
| Equity capital |
149
|
1,312
|
2,067 |
| - share capital |
510
|
509
|
458 |
| Employees (average) |
5
|
5
|
6 |
Financial ratios
| Fiscal year | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
| Solvency |
27.2%
|
86.6%
|
69.6% |
| Turnover per employee |
0
|
0
|
0 |
| Profit as a percentage of turnover | |||
| Return on assets (ROA) |
-238.0%
|
-85.3%
|
-124.4% |
| Current ratio |
119.5%
|
694.1%
|
313.4% |
| Return on equity (ROE) |
-881.9%
|
-101.5%
|
-181.2% |
| Change turnover |
0
|
0
|
0 |
| Change turnover % | |||
| Chg. No. of employees |
0
|
-1
|
-1 |
| Chg. No. of employees % |
0%
|
-17%
|
-14% |
Total value of public sale
| Fiscal year | 2023/12 (consolidated) | 2022/12 (consolidated) | 2021/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.